Efficacy and safety of triple iron chelator (deferoxamine, deferasirox, and deferiprone) versus dual iron chelator (deferoxamine and deferasirox) combination therapy for reducing iron overload in transfusion-dependent beta-thalassaemia with very high iron overload.

Efficacy and safety of deferoxamine, deferasirox, and deferiprone triple iron chelator combination therapy for transfusion-dependent beta-thalassaemia with very high iron overload

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

SLCTR

Registry ID

SLCTR/2023/010

Enrollment

Unknown

Registered

2023-04-19

Start date

2023-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassaemia

Interventions

Patients with transfusion-dependent beta-thalassemia major with very high serum ferritin (>3500ng/mL) attending the Adult and Adolescent Thalassaemia Center of the Colombo North Teaching Hospital, Rag

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female patients. 2. Transfusion-dependent beta-thalassemia major requiring at least eight transfusions per year. 3. Aged over 12 years. 4. Serum ferritin >3500ng/mL in the last two measurements done over the preceding 3-month. 5. Currently on combination therapy with deferoxamine and deferasirox.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating females. 2. History of severe adverse effects to any of the three iron chelator chelators 3. Contraindications for any of the three iron chelators

Design outcomes

Primary

Measure	Time frame
Reduction in iron overload, as measured by a reduction in the serum ferritin concentration after completion of the treatment. [Baseline, after completion of 6-month treatment]	—

Secondary

Measure	Time frame
Reduction in liver iron content as measured by T2* MRI of the liver [Baseline, after completion of 6-month treatment] Reduction in cardiac iron content as measured by T2* MRI of the heart [Baseline, after completion of 6-month treatment] Side effects of trial medication [ After completion of 6-month treatment]	—

Countries

Sri Lanka

Contacts

Public ContactProf Anuja Premawardhena

Professor in Medicine

premawa@hotmail.com+94112961000

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026